{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:02:33Z","timestamp":1790622153338,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011744","name":"National University Health System","doi-asserted-by":"publisher","award":["NCSP3.0\/2026\/NUHS\/SR"],"award-info":[{"award-number":["NCSP3.0\/2026\/NUHS\/SR"]}],"id":[{"id":"10.13039\/501100011744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"publisher","award":["4024002312"],"award-info":[{"award-number":["4024002312"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.modpat.2026.101020","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:46:51Z","timestamp":1781048811000},"page":"101020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune-Related Pathological Features and Predictive Score in Intrahepatic Cholangiocarcinoma Treated With Combined Conversion Immunotherapy"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0929-4757","authenticated-orcid":false,"given":"Wanwan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyneth Shook Ting","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Jun Chen","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8401-7124","authenticated-orcid":false,"given":"Kai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2026.101020_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.modpat.2026.101020_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.modpat.2026.101020_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.modpat.2026.101020_bib4","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/hep.32007","article-title":"Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States","volume":"74","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.modpat.2026.101020_bib5","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.modpat.2026.101020_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2026.101020_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2026.101020_bib9","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2026.101020_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102955","article-title":"The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers","volume":"137","author":"Cabibbo","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.modpat.2026.101020_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib13","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.modpat.2026.101020_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/ijms19051421","article-title":"Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital","volume":"19","author":"Winkelmann","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2026.101020_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000743","article-title":"Intrahepatic cholangiocarcinoma: insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel","volume":"9","author":"Gujarathi","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.modpat.2026.101020_bib18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma","volume":"32","author":"Rawson","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/annonc\/mdz019","article-title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response","volume":"30","author":"Stein","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2026.101020_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.modpat.2026.101020_bib23","author":"Krishnamurti"},{"key":"10.1016\/j.modpat.2026.101020_bib24","author":"Jain"},{"key":"10.1016\/j.modpat.2026.101020_bib25","author":"Murugan"},{"key":"10.1016\/j.modpat.2026.101020_bib26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"issue":"7791","key":"10.1016\/j.modpat.2026.101020_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2026.101020_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100063","article-title":"Standardized pathology screening of mature tertiary lymphoid structures in cancers","volume":"103","author":"Vanhersecke","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.modpat.2026.101020_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00262-024-03929-6","article-title":"Artificial intelligence-based spatial analysis of tertiary lymphoid structures and clinical significance for endometrial cancer","volume":"74","author":"Suzuki","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.modpat.2026.101020_bib30","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1158\/0008-5472.CAN-25-1793","article-title":"Artificial intelligence and multimodality data integration decipher tertiary lymphoid structure maturity in gastric cancer","volume":"85","author":"Wu","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2026.101020_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217491","article-title":"Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: advancing towards clinical application","volume":"613","author":"Cui","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.modpat.2026.101020_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44272-025-00036-0","article-title":"Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"10.1016\/j.modpat.2026.101020_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41379-019-0367-9","article-title":"Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study","volume":"33","author":"Dano","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101020_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104127","article-title":"Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study","volume":"10","author":"Wu","year":"2025","journal-title":"ESMO Open"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:24:59Z","timestamp":1787757899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0893395226000633"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101020","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-Related Pathological Features and Predictive Score in Intrahepatic Cholangiocarcinoma Treated With Combined Conversion Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"101020"}}